We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Equity Crowdfunding Pitches

Showing results
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go: TBC investment: £127,001
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go: Extended investment: £295,000
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go: Extended investment: Withheld
miiCARE is a MedTech specialising in AI applied to geriatrics (elderly care). Its key product miiCUBE offers cutting-edge home-based and customised healthcare, helping the elderly enjoy their independence while being comprehensively connected to their families, friends, and neighbours. The company aims to provide these benefits to one billion people by 2028, comprising older people, family members and carers. Till date, miiCARE has secured partnerships with the UK’s largest NHS trust, Ebbsfleet Garden City, O2, Bristol Careline and Microsoft, and won multiple social impacts and digital health awards during the last 12 months. Funds raised will be used mainly for fulfilling pre-orders and close interests for large contracts with corporates, marketing and logistics, product development, sales and salaries.

Pitch Rated

84%

Gold

rating powered by

CROWD RATING™

days to go: Expired investment: £103,672
Reset Paris offers a wide range of high-end wellness services including spas, massage, sports and therapy classes. These services are delivered by highly qualified and experienced professionals with a holistic approach. Workshops based on matters like stress-relief, nutrition, focus, memory and sleep are also provided right at the office. The company has recruited a team of freelance professionals and tested their performance with B2B and B2C customers, developed a CRM platform and started collective classes with exceptional feedback. Reset is well-positioned to grow by selling health weeks to companies and increase its visibility through digital marketing.
days to go: Expired investment: £111,430
Improving the railway construction industry by collecting data to reduce inefficiencies and overspending. Rail Diary is a B2B SaaS product that is designed to analyse information on infrastructure projects to improve particular elements that plague the industry. These include the delivery, commercialisation and the health and safety of projects. Rail Diary allows developers to monitor ongoing costs, forecast for the future and reduce the number of claims made. Rail Diary will generate revenue via a monthly subscription model ranging from £45 to £150, plus project fees.
days to go: Expired investment: £50,544
Her.9 is a Direct-To-Consumer (DTC) female technology brand that caters to the needs of women during pregnancy. It cites research arguing that up to 40% of women taking prenatal vitamins may not be able to absorb the folic acid within the UK’s leading pregnancy brand. Her.9 aims to resolve this by employing DUOCAP technology. The company asserts that DUOCAP is a capsule-in-capsule delivery system which contains solubilised prebiotics in the outer capsule and probiotics in the inner capsule. The prebiotic releases immediately and the probiotic releases later allowing for targeted supplement delivery in the body. The prenatal supplements market is set to be worth $56 billion globally by 2024. Her.9 aims to be a notable contender in this segment. The company is raising investment to build its already established partnerships and execute its marketing strategy effectively.

Pitch Rated

50%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: £215,946
Buildy is an online platform that aims at making construction hiring easy by eliminating the expensive middlemen, thereby, saving time and money for both employers and employees. The platform was shortlisted as the Best Recruitment Innovation at Building Innovation Awards. Buildy has already signed up around 100 tradespeople and 46 employers. The company will streamline the hiring process through automation of job by bidding for jobs, matching algorithms, ratings, online chat, reviews, and providing the skilled workers and tradespeople more control via a better user interface. With the proceeds, the company will seek to fast track the Buildy app and help the company become the top recognised brand in construction staff hiring.
days to go: Expired investment: £17,380
DNApal is a personalised diet, health and fitness app that combines DNA infomation with other factors like age, weight, diet, family history and health goals. Two of the largest consumer DNA companies, 23andMe and Ancestry.com, have tested over 18m people. DNApal is capable of interpreting DNA results from these companies to provide precise recommendations on how to improve diet, hormone balance, weight loss, sleep, fitness & more. The company also won the best pitch at VentureFest 2019 at Oxford Brookes University. DNApal is aiming to launch MVP in January 2020 (iOS). The company is also aiming to recommend further testing and specific supplements where necessary and offer 1:1 consultations with a specialist. With the fund raised, DNApal plans to develop the full scope of the app, weekly goals, content challenges to keep users committed.

Pitch Rated

70%

Overall

rating powered by

CROWD RATING™

days to go: Expired investment: £49,990
Nutrifix is an app that locates healthy meals nearby or selects recipes or delivery options all tailored to you bodies needs. The app is like having a personal nutritionist in your pocket and is in a growing sector as the global value of mobile health solutions is set to reach 83,000,000,000 by 2022.

Pitch Rated

70%

Overall

rating powered by

CROWD RATING™

days to go: Expired investment: £194,310
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph